Mid-Regional pro-Adrenomedullin (MR-proADM), C-Reactive Protein (CRP)

and Other Biomarkers in the Early Identification of Disease Progression in

COVID-19 Patients in the Acute NHS Setting

- 4 Nathan Moore 1#*, Rebecca Williams 1#, Matilde Mori², Beatrice Bertolusso¹, Gabrielle Vernet¹, Jessica Lynch¹,
- 5 6 Peter Philipson³, Thomas Ledgerwood¹, Stephen P. Kidd¹, Claire Thomas¹, Veronica Garcia-Arias¹, Michelle 7

Young⁴, Kordo Saeed^{2,5}, Kirsty Gordon¹, Nicholas Cortes^{1,2,6,7}

- 9 ¹Hampshire Hospitals NHS Foundation Trust, Basingstoke and North Hampshire Hospital, Basingstoke, UK
- 10 ²University of Southampton, School of Medicine, UK
- 11 ³Newcastle University, School of Mathematics, Statistics & Physics, UK
- ⁴Whittington Hospital, London, UK 12
- 13 ⁵University Hospital Southampton NHS Foundation Trust, Southampton, UK
- ⁶Gibraltar Health Authority, Gibraltar, UK 14 15
 - ⁷University of Gibraltar, Gibraltar, UK
- *Joint first authors 18
- 19 *Corresponding author:
- 20 Nathan.Moore@hhft.nhs.uk
- 21 01256 473202

1

2

3

8

16 17

22 23

24

25 26 27

28

29

30

31 32

33

34

35

36

37 38

39

40

41

42 43

44

45

46 47 48 Keywords: MR-proADM, SARS-CoV-2, COVID-19, Mortality, Biomarkers, Emergency Department, Disease progression

Aims: There is a lack of biomarkers validated for assessing clinical deterioration in COVID-19 patients upon presentation to secondary or tertiary care. This evaluation looked at the potential clinical application of C-Reactive Protein, Procalcitonin, Mid-Regional pro-adrenomedullin (MR-proADM) and White Cell Count to support prediction of clinical outcomes.

Methods: 135 patients presenting to Hampshire Hospitals NHS Foundation Trust between April and June 2020 confirmed to have COVID-19 via RT-qPCR were included. Biomarkers from within 24 hours of admission were used to predict disease progression by Cox regression and area under the receiver operating characteristic (AUROC) curves. The endpoints assessed were 30-day all-cause mortality, intubation and ventilation, critical care admission and non-invasive ventilation (NIV) use.

Results: Elevated MR-proADM was shown to have the greatest ability to predict 30-day mortality adjusting for age, cardiovascular, renal and neurological disease. A significant association was also noted between raised MR-proADM and CRP concentrations and the requirement for critical care admission and non-invasive ventilation.

Conclusions: The measurement of MR-proADM and CRP in patients with confirmed COVID-19 infection upon admission shows significant potential to support clinicians in identifying those at increased risk of disease progression and need for higher level care, subsequently enabling prompt escalation in clinical interventions.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Introduction

Since initial reports of a cluster of pneumonia cases arising from Wuhan, Hubei and the subsequent identification of the causative *betacoronavirus*, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 100 million people globally and directly resulted in the deaths of approximately 2·3 million by January 2021.

The progressive multi-organ failure associated with SARS-CoV-2 mortality is driven in part by significant inflammation and microvascular thrombosis. Presence of SARS-CoV-2 within the endothelium can cause a secondary endotheliitis and an impairment of vascular blood flow, a pro-thrombotic state and vascular leakage. During endotheliitis there is elevation of biomarkers, such as neutrophil extracellular traps, that can lead to microvascular thrombosis and inflammation. ²

Adrenomedullin is a peptide that has been shown to have a role in preserving the integrity and stability of the endothelium after severe infection. Furthermore, it has potent vasodilatory properties, as well as having a role in immunomodulation and metabolic regulation. It is upregulated in several pathogenic processes, including sepsis and the progression of septic patients towards multi-organ failure.³⁻⁵

The novel biomarkers mid-regional proadrenomedullin (MR-proADM) has also been shown to be predictive of poor clinical outcomes in patients with sepsis and infections involving the respiratory^{6,7} and urinary^{8,9} systems. Similarly, it has been demonstrated during non-infective processes such as heart failure and kidney injury. ¹⁰ As a precursor amino acid sequence that splits from proadrenomedullin, MR-proADM is used as a surrogate marker for adrenomedullin. It can be measured via an automated immunofluorescent assay, as levels are directly proportional to adrenomedullin which rapidly breaks down in blood.

The instigation of an appropriate management plan is dependent on an adequate assessment of the infection severity, which is determined by the host pathophysiological response and the virulence of the organism causing infection.

However, infection is a dynamic process with infection severity changing over time within an individual. As infection progresses, patients may transition from low severity to high severity which if not identified, may lead to delayed or inappropriate therapy.

Therefore, biomarkers that could help stratify risk of disease progression are of clinical interest as they may help guide appropriate early management and patient placement within hospital. A recent study by Saeed *et al.* found that the measurement of MR-proADM could effectively predict disease progression; identifying those at increased risk of mortality, those who would need ICU admission and those requiring a longer length of stay in hospital. Furthermore, they identified its potential use in facilitating early discharge from hospital, with no increase in mortality. ¹¹

The aim of this study was to assess the effectiveness of a number of biomarkers, both established and emerging, in the acute setting as prognostic markers to support clinicians in the early identification of patients with Covid-19 at risk of mortality, ICU admission and ventilation.

Methods

Study Design and Data Collection

In this observational study, we identified patients confirmed to have SARS-CoV-2 at a district general hospital, Hampshire Hospitals NHS Foundation Trust, during the first wave of the virus between April and June 2020. SARS-CoV-2 was detected by real-time reverse-transcription PCR (rRT-PCR) using the COVID-19 genesig® Real-Time PCR assay (Primerdesign Ltd, Chandler's Ford, UK). This resulted in 135 eligible consecutive patients. All blood samples analysed were collected as part of routine clinical care on admission to hospital. Measurement of C-reactive protein (CRP) on serum samples was performed on ADVIA 2400 analysers; procalcitonin (PCT) on Centaur XP analysers and full blood count (FBC) and differential white blood cell counts were performed on Ethylenediaminetetraacetic acid (EDTA) samples on Siemens Advia 2120i (all Siemens Healthineers, Tarrytown, New York, USA). Measurement of MR-proADM was performed (within 72hours of collection, in line with manufacturer's guidance) on EDTA blood samples taken on admission using

an immunoassay (B.R.A.H.M.S. KRYPTOR™, Thermo Fisher Scientific, Henningsdorf, Germany). Those performing the assays were blinded to clinical outcomes. Where these variables had not been requested by the responsible clinician attempts were made to locate the original sample and perform the assay, within twenty-four hours.

Patients were followed up until discharge, with demographics, comorbidities, admission and discharge dates, non-invasive ventilation (NIV) use, need for intubation and ventilation, admission to ICU and mortality data being anonymously collected. Clinicians caring for the patients were unaware that outcome data was being collated in relation to the above biomarkers.

Statistical Analysis

Cases and controls were determined by outcome variables during univariate and multivariate Cox Regression. However, this was only performed for clinical outcomes with a sufficiently high event per variable ratio. 12,13 Time to event analysis was right-censored at 30 days. The Cox proportional hazard models were checked for proportionality by correlating sets of scaled Schoenfeld residuals with time, to test for independence between residuals and time. Where proportionality was not met stratification was performed as necessary. Hazard ratios and C-index score were calculated with corresponding 95% confidence intervals. Confounding variables for the multivariate analysis were selected based on those that were significant upon univariate logistic regression following Bonferroni correction, with a p-value of <0.005.

Symmetrically distributed variables were reported using the mean (standard deviation), whereas variables exhibiting a skewed distribution were reported using the median [first quartile – third quartile]. The Chi-square test (χ 2) was used to assess differences in categorical variables in the demographics and clinical characteristics between those who did and did not die within 30 days, with the Mann-Whitney U test being used to assess differences in continuous variables and Student's T-test for age.

Data analysis was performed using R version 4.0.1.

Receiver operating characteristic (ROC) curves with area under the curve (AUC) analysis was used to determine predictive value for each clinical endpoint with 95% confidence intervals to establish significance. To investigate if individual biomarkers offer a significant improvement in predicting an adverse outcome over a model incorporating previously identified confounding variables, as outlined above, AUC analyses were compared using a bootstrap method.

Results

Samples from 135 patients in total were analysed with a mean age of $64 \cdot 6$ years and a predominance of males $(51 \cdot 9\% \text{ male vs } 48 \cdot 1\% \text{ female})$. The patient group included 105 who had survived by thirty days post admission and 30 who had died by this timepoint. The characteristics of the patient cohort are described in Supplementary Table 1.

Median biomarker concentrations in this group showed elevated median CRP 59mg/L (Q1-Q3 range 17 – 143) and MR-proADM 1·02 nmol/L (Q1-Q3 range 0·71 - 1·61); median levels within normal clinical ranges for total white blood cell count $7 \cdot 1 \times 10^9$ /L (Q1-Q3 range $5 \cdot 2 - 9 \cdot 65$), neutrophils $5 \cdot 31 \times 10^9$ /L (Q1-Q3 range $3 \cdot 51 - 7 \cdot 66$) and PCT 0·13ng/mL (Q1-Q3 range $0 \cdot 07 - 0 \cdot 41$) but a suppressed median lymphocyte count $0 \cdot 98 \times 10^9$ /L (Q1-Q3 range $0 \cdot 70 - 1 \cdot 36$).

Twenty-five of these patients were enrolled into the RECOVERY trial with 9 receiving standard care, 6 received hydroxychloroquine, 6 received Lopinavir-Ritonavir and 3 received Azithromycin, all of which were deemed to have no clinical benefit. ¹⁴⁻¹⁶ One patient received dexamethasone as part of the RECOVERY trial. Otherwise, none of the patients received other immunomodulation, including IL-6 inhibitors (tocilizumab or sarilumab), IL-1 inhibitors (such as anankinra) or convalescent plasma.

Multivariate Cox regression adjusted for age, cardiovascular disease, renal disease and neurological disease. Proportionality was checked for all Cox regression models and stratification performed as necessary.

MR-proADM

For this novel biomarker Saeed et al¹¹ have previously derived and proposed, in a non-COVID-19 acute patient population, a cut-off of 1.54 nmol/L as a predictor of elevated mortality, higher rate of ICU admission and longer length of stay. Applying this cut-off to our COVID-19 patient population shows significantly (p = 1.59×10^{-5}) lower mortality rate of 11.11% (N=11) in the patients with MR-proADM values < 1.54 nmol/L (N=99 (73.33%)) compared to a higher mortality rate of 52.78% (N=19) in patients (N=36, (26.67%)) with

MR-proADM values equal to or exceeding a cut-off of 1.54 nmol/L. None of the patients who died (N=30) had a MR-proADM value below the pre-defined threshold of < 0.88 nmol/L (p = 1.61×10^{-9}), previously proposed in a non-COVID-19 population by Saeed et al¹¹ as a potential cut-off for identifying patients at very low risk for deterioration and no mortality.

Of interest, fifty-two (38·52%) patients with MR-proADM values of <0.88 nmol/L had a median inpatient stay of 4 days (interquartile range [IQR] 0.75 - 9 days), representing a significantly shorter length of stay than those with an MR-proADM of >0.88 nmol/L whose median stay was 12 days (IQR 5 - 22.5 days), p <0.00001.

30 Day Mortality

Supplementary Table 1 compares the patient demographics and clinical characteristics between survivors and non-survivors. Of note CRP, PCT and MR-proADM were all significantly raised amongst those that did not survive at day 30.

Univariate Cox regression analysis found MR-proADM to have the greatest ability to predict 30 day mortality (Wald $20\cdot3$, HR $1\cdot5455$ [$1\cdot279-1\cdot868$]), with CRP also proving effective at predicting 30 day mortality (Wald $4\cdot02$, HR $1\cdot0034$ [$1\cdot000-1\cdot007$]) as shown in Table 2.

Although PCT was significant for univariate Cox regression analysis (Wald 11·54, HR 1·0898 [1·037-1·145]), the assumption of proportional hazards was not supported for PCT. Rather than attempting to estimate a time-dependent coefficient in order to include covariates with time-varying coefficients multivariate analysis was not performed. Both MR-proADM (Wald 23·735, HR 1·809[1·454-2·407]) and CRP (Wald 12·166, HR 1·0069[1·003-1·011]) remained significant for predicting 30 day mortality following adjustment for age, cardiovascular disease, renal disease and neurological disease (Table 3). Similarly, lymphocyte count was significant in predicting 30 day mortality after adjusting for co-variates (Wald 6·6564, HR 1·1213[1·028-1·223]).

MR-proADM offered a significant improvement in predicting 30 day mortality over a model combining age, renal disease, cardiovascular disease and neurological disease with an AUC of 0.874 (p=0.01727), whereas CRP did not offer an improvement (p=0.1464).

Intubation and Ventilation

Elevated MR-proADM (Wald 12·37, HR 1·6015[1·232-2·082]) and CRP (Wald 16·57, HR 1·0069 [1·004-1·010]) were both associated with an increase in the need for intubation and ventilation when performing univariate cox regression. No firm conclusions are offered here from a multivariate analysis for prediction of need for intubation and ventilation due to the lower number of events per predictor variable, though the results are suggestive for both MR-proADM and CRP having efficacy in predicting the need for intubation.

Admission to Critical Care

On univariate analysis only CRP demonstrated a significant association with a requirement for admission to critical care (Wald 15·83, HR [1·0055-1·008]), which was maintained once controlled for covariates, however proportionality was affected by renal disease (Chisq 4·2243, p=0·04), which was therefore taken out by stratification (Wald 22·062, HR 1·0078[1·005-1·011]). Although insignificant on univariate analysis MR-proADM (Wald 3·2, HR 1·257[0·978-1·615]) did exhibit a significant association with a requirement for critical care once covariates were controlled for (Wald 10·151, HR 1·5451 [1·182-2·019]).

Only CRP provided an improvement over the previously described combined model with an AUC of 0.8026 (p=0.012).

Non-Invasive Ventilation

Once again elevated CRP (Wald 15·53, HR 1·0061[1·003-1·009]) and MR-proADM (Wald 11·62, HR 1·4992[1·188-1·892]) were associated with requirement for NIV following univariate analysis, with both CRP (Wald 18·293 HR 1·0081[1·004-1·012]) and MR-proADM (Wald 30·393, HR 2·5230[1·816-3·506]) both retaining significance on multivariate analysis. Lymphocyte count was not a constant hazard and so further analysis was omitted rather than estimating a time-dependent coefficient.

Both CRP and MR-proADM offered an improvement over the combined model with AUCs of 0.8544 (p=0.000375) and 0.8139 (p=0.001052) respectively.

Table 1. Univariate Cox regression for prediction of 30-day mortality, requirement of critical care, NIV and intubation and ventilation using biomarkers in baseline bloods

Biomarker	Patients (N)	Cases (N)	Wald	D.F.	C-index [95% CI]	HR [95% CI]	p-value	
Prediction of 30-day mortality								
MR-proADM	135	30	20.3	1	0.811 [0.746-0.876]	1.5455 [1.279–1.868]	6·64e-6	
CRP ¹	135	30	4.02	1	0.613 [0.515-0.711]	1.0034 [1.000-1.007]	0.0449	
PCT ²	116	26	11.54	1	0.621 [0.511-0.731]	1.0898 [1.037-1.145]	0.000681	
Neutrophils	135	30	0.73	1	0.549 [0.445-0.653]	0.9555 [0.861-1.061]	0.394	
Lymphocytes	135	30	3.53	1	0.448 [0.338-0.558]	1.0920 [0.996-1.197]	0.0603	
Prediction of requ	iiring critica	al care adm	ission					
MR-proADM	135	31	3.2	1	0.614 [0.518-0.710]	1.2570 [0.978-1.615]	0.0737	
CRP ¹	135	31	15.83	1	0.716 [0.624-0.808]	1.0055 [1.003-1.008]	0.0000695	
PCT ²	116	31	0.03	1	0.687 [0.595-0.779]	1.0050 [0.951-1.062]	0.86	
Neutrophils	135	31	0.37	1	0.609 [0.511-0.707]	1.0183 [0.960-1.080]	0.544	
Lymphocytes	135	31	2.52	1	0.465 [0.357-0.573]	1.0759 [0.983-1.178]	0.113	
Prediction of requ	Prediction of requiring NIV							
MR-proADM	135	23	11.62	1	0.726 [0.634-0.818]	1.4992 [1.188-1.892]	0.000651	
CRP ¹	135	23	15.53	1	0.725 [0.617-0.833]	1.0061 [1.003-1.009]	0.0000813	
PCT ²	116	22	0.1	1	0.772 [0.682-0.862]	1.0098 [0.952-1.072]	0.747	
Neutrophils	135	23	0.06	1	0.432 [0.324-0.540]	0.9883 [0.901-1.085]	0.804	
Lymphocytes	135	23	4.81	1	0.552 [0.442-0.662]	1.0991 [1.010-1.196]	0.0283	
Prediction of intu	bation and	ventilation						
MR-proADM	135	16	12.37	1	0.748 [0.650-0.846]	1.6015 [1.232-2.082]	0.000435	
CRP ¹	135	16	16.57	1	0.745 [0.614-0.876]	1.0069 [1.004-1.010]	0.0000469	
PCT ²	116	16	0.63	1	0.836 [0.746-0.926]	1.0215 [0.969-1.077]	0.429	
Neutrophils	135	16	0.43	1	0.641 [0.514-0.768]	1.0259 [0.950-1.107]	0.513	
Lymphocytes	135	16	0.09	1	0.468 [0.337-0.599]	0.9415 [0.630-1.408]	0.769	

Table 2. Multivariate Cox regression for prediction of 30-day mortality, requirement of critical care, NIV and intubation and ventilation using biomarkers in baseline bloods

Biomarker	Patients (N)	Cases (N)	Wald	D.F.	C-index [95% CI]	HR [95% CI]	p-value	
Prediction of 30-day mortality								
MR-proADM	135	30	23.736	5	0.827 [0.756-0.898]	1.8709 [1.454-2.407]	1·1e-6	
CRP ¹	135	30	12.166	5	0.788 [0.704-0.872]	1.0069 [1.003-1.011]	0.000487	
PCT	116	26	-	-	-	-	-	
Neutrophils	135	30	0.9235	5	0.808 [0.745-0.871]	0.9445 [0.841-1.061]	0.336303	
Lymphocytes	135	30	6.6564	5	0.791 [0.713-0.869]	1.1213 [1.028-1.223]	0.009879	
Prediction of req	uiring critica	al care adn	nission					
MR-proADM	135	31	10.151	5	0.713 [0.621-0.805]	1.5451 [1.182-2.019]	0.00144	
CRP ¹	135	31	22.062	4	0.775 [0.702-0.848]	1.0078 [1.005-1.011]	2.64e-6	
PCT ²	116	31	0.6084	5	0.715 [0.631-0.799]	1.0254 [0.963-1.092]	0.43564	
Neutrophils	135		0.5761	5	0.686 [0.596-0.776]	1.0221 [0.966-1.081]	0.44772	
Lymphocytes	135	31	1.4066	5	0.689 [0.599-0.779]	1.0638 [0.961-1.178]	0.23544	
Prediction of req	Prediction of requiring NIV							
MR-proADM	135	23	30.393	5	0.828 [0.740-0.916]	2.5230 [1.816-3.506]	3.53e-8	
CRP ¹	135	23	18.293	5	0.799 [0.725-0.873]	1.0081 [1.004-1.012]	1·89e-5	
PCT ²	116	22	1.39	5	0.755 [0.659-0.851]	1.0454 [0.971-1.125]	0.2383	
Neutrophils	135	23	0.0266	5	0.72 [0.616-0.824]	0.9923 [0.905-1.089]	0.8706	
Lymphocytes	135	23	-	-	-	ı	ı	
Prediction of intu	Prediction of intubation and ventilation							
MR-proADM	135	16	22.648	5	0.793 [0.687-0.899]	2.2457 [1.609-3.134]	1.94e-6	
CRP ¹	135	16	18.318	5	0.803 [0.713-0.893]	1.0088 [1.005-1.013]	1·87e-5	
PCT ²	116	16	2.241	5	0.715 [0.617-0.813]	1.0558 [0.983-1.134]	0.134	
Neutrophils	135	16	0.4543	5	0.665 [0.563-0.767]	1.0254 [0.953-1.103]	0.500	
Lymphocytes	135	16	0.2663	5	0.67 [0.554-0.786]	0.8260 [0.400-1.707]	0.606	

¹ C-reactive protein

239

² Procalcitonin

Table 3. Univariate area under receiver operating characteristic curve data for predicting various outcomes from baseline bloods

Biomarker	Patients (N)	Cases (N)	D.F.	AUC [95% CI]
30 day mortality				
MR-proADM	135	30	1	0.8441 [0.7761-0.9122]
CRP ¹	135	30	1	0.6132 [0.5066-0.7198]
PCT ²	116	26	1	0.6212 [0.4963-0.7460]
Neutrophils	135	30	1	0.5503 [0.4356-0.6650]
Lymphocytes	135	30	1	0.5629 [0.4373-0.6884]
Critical Care Admission				
MR-proADM	135	31	1	0.594 [0.4873-0.7007]
CRP ¹	135	31	1	0.7238 [0.6213-0.8263]
PCT ²	116	31	1	0.6856 [0.5771-0.7941]
Neutrophils	135	31	1	0.6158 [0.5104-0.7213]
Lymphocytes	135	31	1	0.5296 [0.4147-0.6446]
NIV				
MR-proADM	135	23	1	0.7189 [0.617-0.8209]
CRP ¹	135	23	1	0.722 [0.6068-0.8373]
PCT ²	116	22	1	0.7706 [0.6734-0.8677]
Neutrophils	135	23	1	0.5615 [0.4505-0.6726]
Lymphocytes	135	23	1	0.5646 [0.4476-0.6817]
Intubation and Ventilatio	n			
MR-proADM	135	16	1	0.75 [0.6434-0.8566]
CRP ¹	135	16	1	0.7545 [0.6059-0.903]
PCT ²	116	16	1	0.8497 [0.7565-0.9429]
Neutrophils	135	16	1	0.6476 [0.5104-0.7848]
Lymphocytes	135	16	1	0.468 [0.324-0.612]

Table 4. Multivariate area under receiver operating characteristic data for predicting various outcomes from baseline bloods

Biomarker	Patients (N)	Cases (N)	D.F.	AUC [95% CI]	Bootstrap
30 day mortality					•
MR-proADM	135	30	5	0.874 [0.8085-0.9395]	0.01727
CRP ¹	135	30	5	0.8441 [0.769-0.9192]	0.1464
PCT ²	116	26	5	0.8406 [0.7619-0.9193]	0.06908
Neutrophils	135	30	5	0.8394 [0.7667-0.9121]	0.1417
Lymphocytes	135	30	5	0.8448 [0.7716-0.918]	0.1056
Critical Care Admis	ssion				
MR-proADM	135	31	5	0.7466 [0.6553-0.8379]	0.1457
CRP ¹	135	31	5	0.8026 [0.7256-0.8796]	0.012
PCT ²	116	31	5	0.7632 [0.6747-0.8517]	0.1465
Neutrophils	135	31	5	0.7252 [0.6359-0.8145]	0.2458
Lymphocytes	135	31	5	0.7317 [0.6413-0.8221]	0.2132
NIV					
MR-proADM	135	23	5	0.8544 [0.7727-0.9362]	0.000375
CRP ¹	135	23	5	0.8139 [0.7374-0.8904]	0.001052
PCT ²	116	22	5	0.7872 [0.6884-0.8861]	0.03331
Neutrophils	135	23	5	0.7418 [0.6341-0.8496]	0.07907
Lymphocytes	135	23	5	0.7519 [0.6461-0.8578]	0.05353
Intubation and Vent	tilation				
MR-proADM	135	16	5	0.812 [0.7071-0.9169]	0.005858
CRP ¹	135	16	5	0.8183 [0.7176-0.9189]	0.002934
PCT ²	116	16	5	0.7256 [0.6193-0.8319]	0.1324
Neutrophils	135	16	5	0.6817 [0.576-0.7874]	0.2557
Lymphocytes	135	16	5	0.6838 [0.5664-0.8012]	0.2675

241 242

243

244 245 246

247

248

249 250

251 252

253

254

255 256

257

258

259

260

261

262

Our study demonstrates that use of biomarkers, both established and novel, has significant potential to support clinical decisions and aid in identification of COVID-19 patients at both high and low risk for disease progression. Of the biomarkers evaluated, elevated MR-proADM and CRP concentrations showed the greatest potential for clinical application for utilisation to aid prediction of 30-day mortality, critical care admission requirement and need for both invasive and non-invasive ventilation.

Of these, on multivariate regression analysis MR-proADM concentration showed the strongest association with an increased 30-day mortality, requirement for non-invasive and invasive ventilation, with CRP showing the strongest association with critical care admission. Our data are also suggestive of an association between elevated MR-proADM and CRP concentration with a progression to being intubated and ventilated, though more cases are required to verify this by controlling for covariates. This is consistent with previous studies that have shown increased MR-proADM levels to be predictive of intensive care requirement in septic patients.¹⁷ Gonzalez del Castillo et al. identified MR-proADM to have the strongest association for ICU admission and

mortality compared to other blood biomarkers in bacterial infections; with concentrations of >1·77nmol/L having significantly higher rates of ICU stay (8·1% vs 1·6%; p<0·001) and disease progression (29·7% vs 4·9%; p<0·001) compared to low MR-proADM concentrations. Application of these and our own findings, applying previously derived thresholds of 0·88 and 1·54nmol/L may support clinicians with decisions regarding earlier transfer of selected patients to wards with staff with experience in non-invasive ventilation, earlier transfer to critical care and dependent on emerging trial data, potentially those who are at low risk of deterioration suitable for ambulant monitoring. Similarly, subject to future studies, biomarker concentrations may have significant value in signalling patients suitable for earlier commencement of targeted therapies, including antiviral treatments (e.g. remdesivir) or immunomodulation with high dose steroids or interleukin-6 inhibitors (e.g. tocilizumab & sarilumab); in the NHS the latter are subject in the UK to specific inclusion criteria which includes physiological derangement and requirement for respiratory support. Page 19.20

Previous studies examining the clinical utility of MR-proADM have focussed on predicting adverse events, primarily in patients with a diagnosis of community-acquired pneumonia and elevated MR-proADM levels, ⁴ reflecting the development of organ dysfunction. However, these patients typically have had low rates of severe viral infection. ^{11, 21} We have shown commensurate results in individuals diagnosed with SARS-CoV-2 infections. This may be explained by the development of endothelial dysfunction during SARS-CoV-2 infection, for which endoreticular stress and the activation of the unfolded protein response is a significant inducer. Endothelial dysfunction is associated with complications of Covid-19 including ARDS, thromboembolism and vascular disease, with Adrenomedullin known to be a regulator of vascular tone and the integrity and stability of the endothelial barrier.

The early recognition of potential for deterioration in patients infected with SARS-CoV-2 is invariably challenging given the varied clinical course of the disease; particularly with the currently unpredictable potential for deterioration during the second and third weeks of disease. As such, a reliable indicator for early identification of patients at risk of deterioration or a more severe illness trajectory could be of great value, in allowing for earlier targeted intervention or escalation of treatment.

The study has several limitations. Primarily, a higher event per variable ratio is desirable, fortunately however stratification was only needed for one covariate. Greater power could be achieved through higher participant numbers or through examining serial results over time. A multi-centre study with more patients could also allow for prediction of progression from NIV to intubation. It is a retrospective study; it remains to be seen whether application of such biomarkers into clinical diagnostic and management pathways will deliver the potential expected benefits. Clinician confidence in use of such biomarkers to support decisions has to be developed and evidenced in clinical practice.

MR-proADM and CRP may have other clinical utility worth exploring, such as whether measurement of these has use in facilitating earlier discharges¹¹ in individuals with low concentrations or whether a delta change in concentrations could be used to guide decisions on weaning ventilatory support and also the de-escalation or stopping of antibiotics to mitigate against potential future antimicrobial resistance.

Conclusions

Biomarker measurement, in particular MR-proADM, in patients infected with SARS-CoV-2 upon presentation to secondary care shows significant promise in allowing early identification of those at increased risk of disease progression and mortality, possibly providing a tool to support clinical decisions regarding therapeutic interventions and level of care setting. Additionally, adopting use of biomarkers such as MR-proADM in the acute setting carries potential in allowing identification of those at low-risk for severe disease, facilitating discharge decisions. Further prospective, multi-centre studies are needed to investigate possible exciting clinical applications of this and other biomarkers.

Key Messages

- Admission MR-proADM predicts 30-day mortality in SARS-CoV-2 infection
- Admission MR-proADM predicts critical care requirement in SARS-CoV-2 infection
- Admission MR-proADM predicts NIV requirement in SARS-CoV-2 infection
 - Admission CRP predicts 30-day mortality, NIV and critical care requirement
 - Admission PCT and White Cell Count do not predict clinical outcomes

Author Contributions NAM, MY, KG and NC contributed to the study conception and design. Material preparation was performed by TL. Data collection was performed by RW, MM, BB, GV and JL. Analysis was performed by NAM and PP. The first draft of the manuscript was written by NAM. RW, SPK, CT, VGA, KS, KG and NC commented on previous versions of the manuscript. All authors read and approved the final manuscript.

321

322

323

324

325

326 327

328

329

330

331 332

333

334

335

336

337

Ethical approval Local Hampshire Hospitals NHS Foundation Trust R&D approval was obtained. HRA Approval was sought who deemed an ethical review was not necessary. HRA Approval was subsequently granted for this project (IRAS project ID: 299130). Anonymised confidential patient information was used under the COVID-19 COPI notice issued by the UK Department of Health and Social Care

Conflicts of Interest Thermofisher provided reagent for measurement of MR-proADM free of charge. PP received payment from Thermofisher and KS has received research grants from Pfizer and Thermofisher. However, neither the payment for PP nor the research grants for KS had any role in study conception or design, the collection, management, analysis, or interpretation of the data, in the preparation, review, or approval of the manuscript, or in the decision to submit the manuscript for publication. There are no non-financial interests. Other authors have no conflicts of interest.

- 338 [1] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.
- Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8. 339
- Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular 340 341 traps in COVID-19. JCI Insight. 2020;5(11).
- 342 Gille J, Ostermann H, Dragu A, Sablotzki A. MR-proADM: A New Biomarker for Early
- 343 Diagnosis of Sepsis in Burned Patients. J Burn Care Res. 2017;38(5):290-8.
- 344 Elke G, Bloos F, Wilson DC, Brunkhorst FM, Briegel J, Reinhart K, et al. The use of mid-
- 345 regional proadrenomedullin to identify disease severity and treatment response to sepsis - a
- 346 secondary analysis of a large randomised controlled trial. Crit Care. 2018;22(1):79.
- 347 Elke G, Bloos F, Wilson DC, Meybohm P, Group SCCT. Identification of developing multiple
- 348 organ failure in sepsis patients with low or moderate SOFA scores. Crit Care. 2018;22(1):147.
- 349 Legramante JM, Mastropasqua M, Susi B, Porzio O, Mazza M, Miranda Agrippino G, et al.
- 350 Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia
- 351 in the Emergency Department compared to clinical severity scores PSI and CURB. PLoS One.
- 352 2017;12(11):e0187702.
- 353 Pereira JM, Azevedo A, Basílio C, Sousa-Dias C, Mergulhão P, Paiva JA. Mid-regional [7]
- 354 proadrenomedullin: An early marker of response in critically ill patients with severe community-
- 355 acquired pneumonia? Rev Port Pneumol (2006). 2016;22(6):308-14.
- 356 [8] Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, Delfos NM, Leyten EMS, et
- 357 al. Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary 358 tract infection. J Infect. 2018;77(1):18-24.
- 359 van der Starre WE, Zunder SM, Vollaard AM, van Nieuwkoop C, Stalenhoef JE, Delfos NM, et
- 360 al. Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting
- outcome of febrile urinary tract infection. Clin Microbiol Infect. 2014;20(10):1048-54. 361
- 362 von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, et al.
- 363 Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart 364 failure. Eur J Heart Fail. 2010;12(5):484-91.
- 365 Saeed K, Wilson DC, Bloos F, Schuetz P, van der Does Y, Melander O, et al. The early
- 366 identification of disease progression in patients with suspected infection presenting to the
- 367 emergency department: a multi-centre derivation and validation study. Crit Care. 2019;23(1):40.
- 368 Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox [12]
- 369 regression. Am J Epidemiol. 2007;165(6):710-8.
- Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE, Moons KG, et al. Minimum sample size for 370
- 371 developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med.
- 372 2019;38(7):1276-96.
- 373 Group RC. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a [14]
- 374 randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605-12.
- 375 Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of [15]
- 376 Hydroxychloroguine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-40.
- 377 Group RC. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a
- 378 randomised, controlled, open-label, platform trial. Lancet. 2020.
- 379 [17] Baldirà J, Ruiz-Rodríguez JC, Wilson DC, Ruiz-Sanmartin A, Cortes A, Chiscano L, et al.
- 380 Biomarkers and clinical scores to aid the identification of disease severity and intensive care
- 381 requirement following activation of an in-hospital sepsis code. Ann Intensive Care. 2020;10(1):7.
- Gonzalez Del Castillo J, Wilson DC, Clemente-Callejo C, Román F, Bardés-Robles I, Jiménez I, 382
- 383 et al. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic
- 384 administration or intensive care admission. Crit Care. 2019;23(1):335.
- 385 Improvement NEaN. Interim Clinical Commissioning Policy: Tocilizumab for critically ill
- 386 patients with COVID-19 pneumonia (adults)
- 387 https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-

388 tocilizumab-for-hospitalised-patients-patients-with-covid-19-pneumonia-adults/: NHS England and NHS Improvement; 2021 [389 390 Improvement NEaN. Interim Clinical Commissioning Policy: Sarilumab for critically ill patients [20] with COVID-19 pneumonia (adults) https://www.england.nhs.uk/coronavirus/publication/interim- 391 392 clinical-commissioning-policy-sarilumab-for-critically-ill-patients-with-covid-19-pneumonia-adults/: 393 NHS England and NHS Improvement; 2021 [394 Xie Z, Chen WS, Yin Y, Chan EC, Terai K, Long LM, et al. Adrenomedullin surges are linked to 395 acute episodes of the systemic capillary leak syndrome (Clarkson disease). J Leukoc Biol. 396 2018;103(4):749-59.

397